These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
202 related items for PubMed ID: 20452431
21. Description and characterization of a novel live-attenuated tri-segmented Machupo virus in Guinea pigs. Zaza AD, Herbreteau CH, Peyrefitte CN. Virol J; 2018 Jun 07; 15(1):99. PubMed ID: 29879985 [Abstract] [Full Text] [Related]
23. The roles of XJ13 and XJ44-specific mutations within the Candid #1 GPC in Junin virus attenuation. Manning JT, Maruyama J, Wanninger T, Reyna RA, Stevenson HL, Peng BH, Mantlo EK, Huang C, Paessler S. Front Immunol; 2023 Jun 07; 14():1172792. PubMed ID: 37334351 [Abstract] [Full Text] [Related]
24. [Phenotypic markers of attenuation in Junin virus strains recently isolated from individuals vaccinated with Junin Candid#1 strain]. Gamboa GS, Ambrosio AM, Maiza AS, Mariani M, Rodrigues Garcia Armôa G, Saavedra Mdel C. Medicina (B Aires); 2013 Jun 07; 73(4):303-9. PubMed ID: 23924527 [Abstract] [Full Text] [Related]
29. A single mutation (V64G) within the RING Domain of Z attenuates Junin virus. Hallam SJ, Manning JT, Maruyama J, Seregin A, Huang C, Walker DH, de la Torre JC, Paessler S. PLoS Negl Trop Dis; 2020 Sep 07; 14(9):e0008555. PubMed ID: 32976538 [Abstract] [Full Text] [Related]
33. Reverse genetics generation of chimeric infectious Junin/Lassa virus is dependent on interaction of homologous glycoprotein stable signal peptide and G2 cytoplasmic domains. Albariño CG, Bird BH, Chakrabarti AK, Dodd KA, White DM, Bergeron E, Shrivastava-Ranjan P, Nichol ST. J Virol; 2011 Jan 07; 85(1):112-22. PubMed ID: 20980515 [Abstract] [Full Text] [Related]
34. Junín virus pathogenesis and virus replication. Grant A, Seregin A, Huang C, Kolokoltsova O, Brasier A, Peters C, Paessler S. Viruses; 2012 Oct 19; 4(10):2317-39. PubMed ID: 23202466 [Abstract] [Full Text] [Related]
35. [Candid#1 vaccine against Argentine hemorrhagic fever produced in Argentina. Immunogenicity and safety]. Enria DA, Ambrosio AM, Briggiler AM, Feuillade MR, Crivelli E, Study Group on Argentine Hemorrhagic Fever Vaccine. Medicina (B Aires); 2010 Oct 19; 70(3):215-22. PubMed ID: 20529769 [Abstract] [Full Text] [Related]
36. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF. Raviprakash K, Marques E, Ewing D, Lu Y, Phillips I, Porter KR, Kochel TJ, August TJ, Hayes CG, Murphy GS. Virology; 2001 Nov 10; 290(1):74-82. PubMed ID: 11883007 [Abstract] [Full Text] [Related]
37. A sindbis virus replicon-based DNA vaccine encoding the rabies virus glycoprotein elicits immune responses and complete protection in mice from lethal challenge. Saxena S, Dahiya SS, Sonwane AA, Patel CL, Saini M, Rai A, Gupta PK. Vaccine; 2008 Dec 02; 26(51):6592-601. PubMed ID: 18848857 [Abstract] [Full Text] [Related]
39. Protocol for the Production of a Vaccine Against Argentinian Hemorrhagic Fever. Ambrosio AM, Mariani MA, Maiza AS, Gamboa GS, Fossa SE, Bottale AJ. Methods Mol Biol; 2018 Dec 02; 1604():305-329. PubMed ID: 28986845 [Abstract] [Full Text] [Related]
40. DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Colombage G, Hall R, Pavy M, Lobigs M. Virology; 1998 Oct 10; 250(1):151-63. PubMed ID: 9770429 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]